Less than 10% of individuals who could benefit from weight-loss injections including Wegovy are able to get them, caution the global health agency as it releases its inaugural advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is calling for more widespread and fairer access to GLP-1 medication.
According to projections, over two billion could be living with obesity by 2030 unless action is taken.
"Our new guidelines affirms that obesity is a long-term condition that can be treated with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to broad access to the treatments that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Shortage
Even in the present most favorable outlook, the supply of such drugs could only cover about 100 million people – under 10% of eligible patients, as stated by the health organization.
The guideline encourages nations and manufacturers to increase availability, through measures like voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in several nations in 2026.
How Obesity Injections Function
The injections imitate a biological compound to delay gastric emptying, suppress the appetite and enhance the sense of being full so individuals eat less.
People commonly start to lose weight after several weeks of beginning the regular doses.
Studies points to users may put most of the weight back on after a year of stopping the drug, as their typical appetite return.
Being carrying excess weight increases your chance for experiencing medical conditions, such as diabetes, heart disease, stroke, and certain cancers.
Excess weight concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
